GLP-1 rollup via licensed pharmacies

This is a speed and pricing strategy disguised as market entry. Instead of building a new telehealth stack country by country, AIOS can buy the hard part, which is a locally licensed pharmacy, then drop in the same intake forms, prescribing workflow, refill logic, side effect monitoring, and cold chain shipping playbook that helped Bolt grow from 3,000 to 150,000 active patients in Britain while pricing below Boots and Numan.1 2 3

• The pharmacy license matters because GLP-1 care is not just ads and a video visit. Someone has to legally dispense the drug, manage inventory, ship refrigerated pens, and handle monthly dose increases. Acquiring Bolt let AIOS keep that regulated layer and change the consumer front end fast.1 2
• The UK already showed the playbook. AIOS sold branded GLP-1s at cost, earned gross margins closer to a pharmacy at about 20%, and used low prices to pull demand away from incumbents charging £179 to £299 per month. That is a volume model, not a premium care model.1 2
• Competitors are using the same shortcut from a different angle. Hims & Hers announced plans to acquire ZAVA on June 3, 2025 to get licensed infrastructure across the UK, Germany, France, and Ireland, while Ro tied itself to NovoCare supply instead of winning on lowest price. The market is consolidating around whoever controls the regulated pipe.3 4 5

The next step is a Europe wide rollup where telehealth brands look increasingly similar on the surface, and the real edge shifts to pharmacy ownership, drug sourcing, and eventually generic manufacturing. If AIOS can keep repeating Bolt faster than rivals can lock up supply or licenses, it can turn GLP-1 telehealth from a marketing business into a distribution business.1 3 4 5 6